Ensem Therapeutics, Inc announced that its partner BeiGene has dosed the first five patients in its first-in-human phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of solid tumours. The achievement triggers a milestone payment from BeiGene, which licensed the compound (formerly ETX-197) from Ensem in November 2023. BG-68501 is the first clinical stage compound to emerge from Ensem’s Kinetic Ensemble platform, a suite of novel AI/ML, computational and experimental technologies to uncover cryptic pockets in target proteins for drug discovery.
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of solid tumors. The achievement triggers a milestone payment from BeiGene, which licensed the compound (formerly ETX-197) from ENSEM in November 2023. BG-68501 is the first clinical stage compound to emerge from ENSEM’s Kinetic Ensemble® platform, a suite of novel AI/ML, computational and experimental technologies to uncover cryptic pockets in target proteins for drug discovery.
BeiGene to buy global rights to Ensem`s experimental cancer therapy
WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the promotion of Dr. Shengfang Jin to President and Chief Executive Officer, effective immediately. Dr. Jin has more than 25 years of biotech and pharma leadership experience in oncology and other disease therapeutics development.